MedGenome is India’s leading genetic diagnostics, research and data company, with a focus on improving the health of populations in South Asia and other emerging markets. To meet this goal, it has built the largest database of South Asian genetic variants, through its leadership in genetic diagnostics in India, research partnerships and work as a founding member of GenomeAsia 100K.
MedGenome’s work to provide insights into complex diseases at genetic and molecular level has the potential to be leveraged by researchers and pharmaceutical companies to aid in drug discovery and clinical trials for treatment in the areas of oncology, diabetes, ophthalmology, cardiology and other rare diseases. It has established genome centres in key cities across India to create awareness of genetic testing, and offer relevant and affordable services to help patients manage their health outcomes via genomics and personalised medicine, which represent the future of healthcare.
The LeapFrog Difference
LeapFrog invested in MedGenome in 2020. Our investment has enabled this cutting-edge company to expand access to, and affordability of, its genetic testing services across India, and begin offering diagnostic services in South Asia, the Middle East, Eastern Europe and Africa, enabling the creation of ever more diverse data sets. It will also allow MedGenome to accelerate its drug discovery programs that could significantly impact upon the treatment of cancer and cardiovascular diseases.
MedGenome is just one of the healthcare companies we have invested in. Learn more about the other innovative and impactful businesses LeapFrog has partnered with.